South San Francisco, California, USA, April 6, 2026
First-in-Class Epigenetic Therapy Enters Clinical Development
In a major step forward for precision oncology, IDEAYA Biosciences has announced the first patient enrolled in its Phase 1 clinical trial evaluating IDE574, a potential first-in-class dual inhibitor targeting KAT6 and KAT7. This innovative small molecule therapy is designed to address multiple solid tumor indications, including breast, prostate, colorectal, and lung cancers, all of which represent areas of high unmet medical need.
The dose-escalation study will assess safety, tolerability, pharmacokinetics, and preliminary efficacy of IDE574 as a monotherapy, marking a critical milestone in translating preclinical breakthroughs into clinical application. By targeting epigenetic regulators involved in cancer cell survival and lineage control, IDE574 introduces a novel mechanism of action aimed at overcoming tumor heterogeneity and treatment resistance, which remain key challenges in modern oncology.
Dual KAT6/7 Inhibition Shows Strong Preclinical Potential
IDE574 is engineered as a selective and equipotent dual inhibitor of KAT6 and KAT7, two lysine acetyltransferases that play a critical role in chromatin remodeling and gene expression regulation in cancer cells. Unlike earlier therapies that target KAT6 alone, IDE574 has demonstrated superior anti-tumor activity and durability in preclinical CDX and PDX models, suggesting a more robust therapeutic effect.
Advertisement
The molecule exhibits single-digit to low-teen nanomolar potency, with a high selectivity profile (350–2,000-fold) over related paralogs KAT5 and KAT8, minimizing potential off-target effects and improving safety prospects. Importantly, IDE574 has shown promising activity in tumors with ESR1 mutations, a common mechanism of resistance in hormone receptor-positive breast cancer, where mutation prevalence can reach 10–50%. This highlights its potential as a next-generation targeted therapy capable of addressing drug resistance and disease progression in multiple cancer types.
Expanding Precision Medicine Strategies in Oncology
The initiation of this trial reflects IDEAYA’s broader strategy of developing first-in-class and best-in-class targeted therapies aligned with genetic drivers of cancer. IDE574 is expected to play a central role in the company’s precision medicine pipeline, with potential applications both as a standalone therapy and in combination regimens. The company has identified multiple combination opportunities with other proprietary assets, aiming to enhance treatment efficacy and durability through synergistic mechanisms.
The Phase 1 study will also generate critical data to support future biomarker-driven patient selection, further advancing the field of personalized cancer therapy. With a pipeline of over innovative oncology assets, IDEAYA continues to leverage its expertise in structural biology, bioinformatics, and translational research to develop therapies that are more selective, effective, and tailored to individual patient profiles.
Targeting Resistance and Redefining Cancer Treatment
Cancer treatment resistance remains one of the most significant barriers to long-term therapeutic success. IDE574’s ability to target epigenetic mechanisms underlying tumor evolution and resistance pathways positions it as a potential game-changer in oncology drug development. By modulating chromatin structure and transcriptional programs, the therapy aims to restore sensitivity to treatment and suppress tumor growth at its molecular roots. The advancement of IDE574 into clinical trials underscores the growing importance of epigenetic therapies and synthetic lethality approaches in addressing complex cancers.
As clinical data emerge, IDE574 could help redefine treatment paradigms for patients with advanced solid tumors, particularly those who have exhausted existing therapeutic options. This development marks another important milestone in the evolution of precision medicine and next-generation oncology therapeutics, offering new hope for improved outcomes and long-term disease control.
Source: IDEAYA Biosciences press release
